Podcasts about associate faculty member

The hosts of Ordinary Unhappiness join the podcast to discuss D. W. Winnicott; one of the most influential figures in the history of psychoanalysis in Britain. They explain how Winnicott's work was shaped by the traumatizing effects of World War 2, debates between Anna Freud and Melanie Klein, and the place of mothers in the construction of the British welfare state. We also discuss how this history relates to contemporary struggles over social reproduction and care.Abby Kluchin is Assistant Professor of Philosophy and Religious Studies at Ursinus College in Pennsylvania, where she coordinates the Gender, Women's, and Sexuality Studies program. Abby is a co-founder and Associate Director at Large of the Brooklyn Institute for Social Research. She co-hosts the podcast Ordinary Unhappiness with Patrick.Patrick Blanchfield is a writer, an Associate Faculty Member at the Brooklyn Institute for Social Research, and co-host of Ordinary Unhappiness, a podcast about psychoanalysis, politics, pop culture, and the ways we suffer now. He is also a contributing editor at Parapraxis magazine. SUPPORT: www.buymeacoffee.com/redmedicineSoundtrack by Mark PilkingtonTwitter: @red_medicine__www.redmedicine.substack.com/

This week's episode features a conversation with Sara Bronin, the chair of the Advisory Council on Historic Preservation (ACHP). In this episode she shares her journey through the profession and her interest in historic preservation. She discusses the intersection of architecture and law, specifically focusing on property law and land use law. Sara explains the role of the ACHP as the Federal Historic Preservation Agency and its regulatory and policy functions. She highlights the recent program comment on accessible climate resilient and connected communities, which aims to accelerate the creation of housing and promote energy-efficient and climate-friendly buildings and transportation. Sara also discusses the importance of incorporating Indigenous knowledge into the Section 106 process and the recent resolution of two historic buildings in Chicago.One of the main takeaways for me from this conversation is the importance of public involvement in the Section 106 process. As you'll hear in the episode the public comment period for the Program Comments we discuss is now open. Written feedback or questions on the proposed Program Comment may be emailed directly to program_alternatives@achp.gov through October 9, 2024.Links: ACHP Announcement on draft Program Comment on Accessible, Climate Resilient, Connected Communities Submit program comments via email: program_alternatives@achp.govBloomberg article: Biden Aims to Speed Up Historic Preservation Reviews in ProjectsLatinos in Heritage ConservationTangible Remnants on InstagramTangible Remnants WebsiteLinkedTr.ee for resourcesEarn CEUs for listening to this podcastSignup for Ask Me Anything w/ Nakita ReedGabl Media NetworkSarah Gilberg's MusicBio: Sara C. Bronin was confirmed by unanimous consent by the United States Senate in December 2022 to serve as the 12th chair of the Advisory Council on Historic Preservation. A Mexican American, she is the first person of color to serve in this position. Chair Bronin is on leave from her tenured position at Cornell University, where she serves as a Professor in the College of Architecture Art &; Planning, a Professor in the Rubacha Department of Real Estate, an Associate Faculty Member of the Law School, and an member of the Graduate Faculty in the Field of Architecture. Chair Bronin received a J.D. from Yale Law School, an M.Sc. in Economic and Social History from the University of Oxford, where she was a Rhodes Scholar, and received a B.Arch. and B.A. in the Plan II Liberal Arts Honors Program from the University of Texas at Austin. **Some of the links above maybe Amazon affiliate links, which...

Join Raza Ahmad & Talib Man for Monday's show from 4-6pm where we will be discussing: 'Anti Islam leaders' and 'Space Exploration' Anti Islam leaders Islamophobia is on the rise in Europe. The Islamophobic street movements and political parties have become more popular. Join us as we discuss the rise of anti-Islam movements in Europe and the compatibility of Islam with European civilisation. Space Exploration Over five decades have passed since humans first set foot on the Moon—an unparalleled milestone etched in history. Despite recent perceptions of a diminished global interest in space exploration, the landscape is undergoing a transformation. Enterprising private entities like SpaceX are injecting fresh vitality into the field, pushing the boundaries of what humanity can achieve and reigniting public fascination. Guests: Professor Martin Conway (Professor of Contemporary European History at the University of Oxford, author of a number of books on twentieth-century Europe, including Western Europe's Democratic Age 1945-68) Dr Lucinda King (Space Projects Manager at the University of Portsmouth) Munzaa Alam Professor Clifford Burgess (Professor at McMaster University's department of Physics and Astronomy and Associate Faculty Member at Perimeter Institute for Theoretical Physics) Producers: Maria Ahmad Tooba and Durr-e-Sameen Mirza

In this episode of Medsider Radio, we sat down with Bill Colone, the CEO and Chairman of SinglePass, a company developing an electrocautery device for deep tissue biopsies.Bill previously headed Spinal Singularity, raising over $11 million for product and clinical development. He was VP of R&D at Direct Flow Medical and the President of Endomed, which was sold in 2005. Bill also served in multiple leadership roles at Endologix and holds 13 U.S. patents with more pending. He earned his bachelor's in Chemical Engineering from Arizona State University, where he later served as an Associate Faculty Member and sits on the advisory committee for Chemical and Materials Engineering.In this interview, Bill shares invaluable insights and actionable strategies for building and leveraging an expansive network, optimizing fundraising, and strategically planning for both acquisition and independent growth. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Bill Colone.

On this episode of the psychology Talk Podcast, our guest Dr. Brent Willock takes us on an unprecedented rollercoaster as he discusses his latest book, "The Wrongful Conviction of Oscar Pistorius."Brent Willock earned his doctorate in clinical psychology from the University of Michigan. After several years on staff in the Department of Psychiatry at the University of Michigan Medical Center, he relocated to Toronto to become Chief Psychologist at the university-affiliated C.M. Hincks Treatment Center. He was Adjunct Faculty, York University, Associate Faculty Member, School of Graduate Studies, University of Toronto, and taught at the Ontario Institute for Studies in Education.Prepare to be captivated by a narrative that unravels the complexities of the human mind, law, and justice. With Dr. Willock's expert, psychological analysis, we navigate the intricacies of this gripping story that challenges our understanding of guilt, innocence, sleep, and the capacity of the human mind for dissociation. Dr. Willock explores the Pistorius case through the eyes of neuroscience and psychology. He also provides case law example from the Parks case in Canada from the 1980s, a similar murder trial. This episode, laike his book, is likely to be controversial, but also extremely informative regarding the issues at hand in the Pistorius case, and gives credence to an alternative perspective.Dr. Willock also covers somnambulism and how it plays out over the lifespan, parasomnias, and sleep terrors. This discussion may lead you to question cultural assumptions about waking life and the idea that we are a singularity and in control of our fullness of selves.The Psychology Talk Podcast is a unique conversation about psychology around the globe. Your host Dr. Scott Hoye discusses psychology and mental health trends with practitioners and experts to keep you informed about issues and trends in the industry. Dr. Hoye is a clinical psychologist and the director of Chicago Psychology Services, in Chicago, IL., USA.https://psych-talk.comhttps://www.instagram.com/psychtalkpodcast/https://www.facebook.com/psychtalkpodcasthttps://chicagopsychservices.comThis show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/3571902/advertisement

As a legal nurse consultant, when you go through medical records, you may see indications that an ethics consult was called or that ethical issues were considered. You may also find yourself struggling with aspects of the decisions made regarding the patient and feel the need of advice from an expert in medical ethics. Camille Renella opens the door to this little-understood aspect of medicine. She begins by pointing out that ethics has lower regard than the law in terms of application simply because legal violations generate so many more repercussions. At an earlier time, doctors and administrative personnel didn't even want to deal with issues like setting up ethics committees in their institutions. Today no formal qualifications exist for sitting on such a committee. In contrast, medical ethicists receive formal, usually post-doctoral, education in their field. They look at those who are working around the patient and consider the standard of care and code of ethics of each group of practitioners and how their application of these values can benefit the patient. The need for a clinical medical ethicist particularly arises in continuation of life issues. This can involve conflicts between family members and clinical staff, issues around advanced directives, and other considerations. Camille raises important ethical and practical issues in this informative podcast. It will broaden your perspective about what is involved in medical decisions. Join me in this episode of Ethical Dilemmas in Healthcare: Insights from a Medical Ethicist with Camille Renella What does a medical ethicist do? What are the requirements for sitting on an ethics committee? How do issues of life support get involved with ethics? How do hospital and medical costs impact ethics decisions? How important is the role of intuition in medical ethics? Listen to our podcasts or watch them using our app, Expert.edu, available at legalnursebusiness.com/expertedu. https://youtu.be/rNC2EcuylTI You can still order the recordings for our 7th Virtual Conference! LNC Success™ is a Virtual Conference 3-day event designed for legal nurse consultants just like you! Pat Iyer and Barbara Levin put together THE first Legal Nurse Consulting Virtual Conference in July 2020. They are back with their 7th all-new conference based on what attendees said they'd find most valuable. This new implementation and networking event is designed for LNCs at any stage in their career. Build your expertise, attract higher-paying attorney clients, and take your business to the next level. After the LNC Success™ Virtual Conference, you will leave with clarity, confidence, and an effective step-by-step action plan that you can immediately implement in your business. Your Presenter of Ethical Dilemmas in Healthcare: Insights from a Medical Ethicist with Camille Renella Camille M. Renella is a veteran clinician and former Associate Faculty Member of The MacLean Center for Clinical Medical Ethics at the University of Chicago. Camille completed the Post Doctorate Fellowship in Clinical Medical Ethics at the University of Chicago Pritzker School of Medicine and served as Chief Ethicist in Patient Services at The University of Chicago Hospitals and The University of Chicago Children's Hospital for ten years. Camille has an extensive clinical background in adult, child and home health nursing, as well as Nursing Administration and Multidisciplinary staff education. Camille continues to integrate her background in medicine, law and clinical medical ethics as President of her National Consulting Firm, C.M. RENELLA & ASSOCIATES and now President of Healthcare Competency Program Specialists, LLC. Throughout her career Camille participated in Clinical Outreach Programs in San Juan, Puerto Rico and in Capitol Hill, Washington DC nation-wide initiative. Camille provided presentations at local,

Bill Colone is the CEO and Chairman of Single Pass, a new Orange County-based start-up company developing a unique electrocautery device for use during deep tissue biopsy procedures. Bill formerly served as the CEO at Spinal Singularity, a seed-stage medical device development company in San Clemente, CA. Under Mr. Colone, the company raised over $6.6 million in dilutive funding and over $5.1 million in non-dilutive funding for product development, clinical studies, and regulatory approvals. Prior to Spinal Singularity, he served as the VP of R&D for Direct Flow Medical until its sudden closure in November of 2017. He has over three decades of medical device development experience, including ten years as President of Endomed, until its sale in February 2005. Mr. Colone has vast knowledge of ePTFE and endovascular prostheses and is recognized for his contributions to endoluminal technology and vascular surgery. Prior to Direct Flow Medical, he served as Director of Research and Development, and later Director of Aortic Procedure Development, for Endologix. Mr.Colone directed the development of the Nellix Endovascular Aneurysm Sealing System through design completion, CE trial completion, CE Mark approval, and OUS commercial launch. He also contributed to the procedure development and training for the US IDE investigation centers leading to the fastest enrolled IDE trial for an EVAR device. Mr. Colone holds 13 US patents for medical devices with others pending. He also served as Director of Operations for IMPRA, Inc. (now Bard Peripheral Vascular) prior to founding Endomed. Mr. Colone holds a bachelor's degree in Chemical Engineering from Arizona State University where he is a member of the ASU Advisory Committee for Chemical and Materials Engineering. Mr. Colone also served as an Associate Faculty Member at ASU from 2004 through 2007 and was a Founding Member and Board Member of the Arizona Technology Investor Forum. -- Critical Mass Business Talk Show is Orange County, CA's longest-running business talk show, focused on offering value and insight to middle-market business leaders in the OC and beyond. Hosted by Ric Franzi, business partner at Renaissance Executive Forums Orange County. Learn more about Ric at www.ricfranzi.com. Catch up on past Critical Mass Business Talk Show interviews... YouTube: https://lnkd.in/gHKT2gmF LinkedIn: https://lnkd.in/g2PzRhjQ Podbean: https://lnkd.in/eWpNVRi Apple Podcasts: https://lnkd.in/gRd_863w Spotify: https://lnkd.in/gruexU6m #orangecountyca #mastermind #ceopeergroups #peergroups #peerlearning

Emily A. Rollie Ph.D., Director of Men on Boats at UNO Theatre talks about this history reimagined production made up of non-binary and female cast members!  In addition, we learned about her other role as an Intimacy Choreographer, which is timely and a newer concept to the theatre stage.  Dr. Rollie also serves as an Educator and Faculty Member of the Washington Central State University theatre department, as well as an Associate Faculty Member for Theatrical Intimacy Education.  She has written numerous articles, has served as an Artistic Director at the Independent Actors Theatre, and has a Master's Degree in Theatre at Central Washington University and her Ph.D. at the University of Missouri-Columbia.   Dr. Rollie has many more credits and talents to her name and can be found on her website:  https://www.emilyrollie.com/.  And suffice to say, she has brought her vast talents to this production at UNO Theatre.  In addition, it's perfect timing, since March is Women's History Month to bring such a talented female to our state who has been a resource and advocate for women in theatre, and a gender and sexuality educator.  She was the Assistant Director of Troubling Violence Performance Project (TVPP) a group dedicated to opening lines of communication about issues of relationship violence through the performance of personal narratives.   There's so much to unpack here:  Men On Boats is a history reimagined play about the 1869 exploration of what is known today as the Grand Canyon, as well as learning about Intimacy Choreography from such a talented Creative.  Join us for a great conversation with Emily A. Rollie, Ph.D.! Men On Boats by Jacklyn Backhaus opens February 23rd through March 5th. Performances are February 23-25th, and March 2-4 at 7:30PM; and Feb 26 and March 5th at 2PM. ***** UNO CONTACT INFORMATION:  Website:  UNO Theatre Website Facebook: UNOTheatre on Facebook Instagram: UNO Theatre on Instagram Twitter: UNO Theatre on Twitter For tickets at the door: 6505 University Dr S, Omaha, NE 68182 Walk up to the Box Office Visit the Theatre Box Office, located on the first floor at the south lobby of the Weber Fine Arts Building. The box office opens at 6:30 p.m. on performance nights. To Call for Tickets: Box Office: 402.554.PLAY (7529)   ****** HOW TO LISTEN TO THE PLATTE RIVER BARD PODCAST Listen at https://platteriverbard.podbean.com or anywhere you get your podcasts. We are on Apple, Google, Pandora, Spotify, iHeart Radio, Podbean, Overcast, Listen Now, Castbox and anywhere you get your podcasts. You may also find us by just asking Alexa. Listen on your computer or any device on our website: https://www.platteriverbard.com. Find us on YouTube: https://youtube.com/channel/UCPDzMz8kHvsLcJRV-myurvA. Please find us and Subscribe!

In this episode, Tim sits down with Christopher McGovern, Associate Faculty Member at the New York Conservatory for Dramatic Arts. 

After finishing college, Grattan went to Australia for a year and returned home 12 years later. He lived and worked in Taiwan for 8 years, where he studied Chinese, taught English and eventually set up his own business. He also travelled extensively in South East Asia; often for months at a time.Returning to Ireland in 1998 he bought a training franchise, specialising in leadership and management development. Qualifying as an Executive & Business Coach in 2006 was a natural progression. Coaching also  re-ignited his passion for learning, which was all but extinguished by his 17 years in the formal education system.In 2007 he attended his first coaching event, a talk by Sir John Whitmore, one of the founding fathers of coaching. Sir John articulated three ‘provocations':•      Consumerism (more and more) is not compatible with sustainability (less)•      Quantitative technical advance is way ahead of Qualitative wisdom (our technical capability is way beyond our wisdom in how to use that technology•      Hierarchy is in decay and must be replaced by self-responsibilityHearing these provocations articulated with such clarity, lit a spark in Grattan which still burns to this day.In 2010 after suffering burnout, mindfulness found him. Recognising how beneficial mindfulness was for him personally, he joined Potential Project. With these global leaders in corporate mindfulness, over the next 6 years he trained mindfulness to thousands of people in organisations.Grattan believes we all know there are better ways we could be living and working. Better for our wellbeing. For our loved ones. Our organisations. Our communities. Our planet. If only we weren't too busy to explore them.He invites his clients to step back from the ‘busyness' of their lives and identify what is truly important.He is most interested to work with people who want to be the best FOR the world. People who want to step into their power, and work with the biggest challenges facing humanity - the climate, biodiversity and environmental crises. People who want to contribute to a better world; not just for humanity but also for the more-than-human world.As a Regenerative Leadership Coach, he supports clients to do their own inner transformational work first. When they do, they are best equipped for the challenges of working with these existential threats.He facilitates mission-driven teams and purpose-led organisations. He helps them develop and grow their collective wisdom, and work in ways that contribute to the healing of the planet.  He has pioneered Walk-and-Talk coaching sessions in nature for more than 10 years and virtual Walk-and-Talk sessions since the pandemic began.Integrating neuroscience, mindfulness and nature practices with indigenous wisdom, opens people up to different ways of sensing, feeling, thinking, doing, AND Being. People are then supported to reimagine a better future and a more beautiful world our hearts know is possible.He is an Honorary Life Fellow and a Founding Council Member of the Association for Coaching, Ireland (2007-2015) and was Chair from 2013-2015. He is a Associate Faculty Member with the Irish Management Institute, teaching on their Diploma in Executive Coaching.He has been training the Diploma in Coaching for Performance in Dublin Business School since 2013.He was a Board Member of Mindful Nation Ireland from 2018 to 2021.He is a member of the Climate Coaching Alliance and has protested with his daughter in many of the Fridays for Future Schools Climate Strikes.Find out more about Grattan on Linkedin and his website.

Today's guests: Dwight Newman, Professor of Law, Canada Research Chair in Indigenous Rights in Constitutional and International Law - University of Saskatchewan / Munk Senior Fellow (Constitutional law) with the Macdonald-Laurier Institute Avery Broderick, Associate Professor in the Department of Physics & Astronomy at the University of Waterloo and an Associate Faculty Member at the Perimeter Institute of Theoretical Physics Kelly Sundberg, Associate Professor in the Department of Economics, Justice, and Policy Studies at Mount Royal University Tasha Kheiriddin, National Post Columnist / Max Bell School of Public Policy at McGill Alla Drigola, Director of Parliamentary Affairs and Small Business Policy - Canadian Chamber of Commerce See omnystudio.com/listener for privacy information.

  Chapter 1: Canadians want more flexibility in their work lives The pandemic is making Canadians more comfortable asking employers to accommodate their needs. That’s according to a survey of over 1,000 people commissioned by hiring and jobs site Indeed DOT C-A.  They found people are more comfortable asking for adjusted working hours and more latitude deciding where they want to do that work as well.  GUEST: Jodi Kasten, Managing Director of Indeed Canada Chapter 2: Supermassive black hole's swirling magnetic field  The old adage says a picture is worth a thousand words but a newly released picture of a black hole in space is saying a lot more than that.  GUEST: Avery Broderick, Associate Professor in the Department of Physics & Astronomy at the University of Waterloo and an Associate Faculty Member at the Perimeter Institute of Theoretical Physics Chapter 3: On some BC streets, 30 might soon be the new 50  If there’s one thing guaranteed to get tempers flaring, it’s speed limits.  Saanich has joined Victoria in asking the province for permission to introduce slow zones that restrict motorists to speeds of 30 km/h, as more municipalities debate similar actions.  GUEST: Brent Toderian, former chief planner at the City of Vancouver, founder of Toderian UrbanWORKS Chapter 4: February was another record month for drug overdose deaths This now marks a full year of a sustained spike in the number of overdose deaths connected to the pandemic.  So why aren’t the interventions working? GUEST: Guy Felicella, peer clinical advisor with the BC Centre on Substance Use and Overdose Emergency Response Centre Chapter 5: Getting a giant cargo ship out of the Suez Canal A ship that is almost as long as the C-N Tower is tall is currently run aground in the Suez Canal.  BILLIONS of dollars of goods are shipped through the canal every day but the multi-day blockage has over 150 vessels sitting there waiting.  GUEST: Dr. Sal Marcogliano, adjunct professor with the U.S. Merchant Marine Academy  Chapter 6: Saanich Distillery on Vancouver Island is trying to fend off legal action A distillery on Vancouver Island is trying to fend off legal action over the use of Scottish words to describe their product.  Macaloney’s Caledonian Distillery is facing legal action from the Scotch Whisky Association.  GUEST: Graeme Macaloney, owner of Macaloney’s Caledonian Distillery in Saanich See omnystudio.com/listener for privacy information.

In episode 17 of Mission: Impact, some of the topics that Carol and her guest, Wendy Wolff discussed include: How leading a non-profit differs from leading a for-profit business Awareness vs. action Why people are scared of evaluation Assumptions made when working with communities Changing social norms Where to start evaluation on an organizational level The barriers to evidence-based testing Guest Information:Activating and coordinating community responses to the HIV/AIDS epidemic was how Wendy Wolff began her career in the nonprofit sector. Her early career helped her to build a strong understanding about the value and role of the community in program planning and policy development. She brings nearly 25 years of diverse consulting experiences to her role as Director of Strategic Engagement for Maryland Nonprofits. Wendy has collaborated with government agencies; universities; non-profit organizations; and faith-based organizations to enhance the quality of life within many communities throughout the United States. She uses her strategic thinking skills to help clients synthesize information from wide-ranging sources, reframe problems while uncovering root causes to find refreshing, creative and effective solutions. Over the past two decades, Wendy has helped thousands of organizations and their people to create brighter futures for the communities in which they serve. Her excitement in working with the members of Maryland Nonprofit’s is infectious. She values the genius that each and every person brings to their role in the sector and works diligently to elevate any person that she engages with.  Ms. Wolff holds a Master’s Degree in Public Health from New York University. She has resided as an Adjunct Professor at the University of Denver and as an Associate Faculty Member at Indian River State College. Wendy is a licensed consultant with the Standards for Excellence® Institute. Ms. Wolff’s first book, The Letter Writing Project (Blooming Twig Books), was published in August 2014. Evaluation Resources https://sphweb.bumc.bu.edu/otlt/mph-modules/sb/behavioralchangetheories/behavioralchangetheories6.html https://www.cdc.gov/eval/framework/index.htm http://www.gracesocialsector.com/missionimpact/is-your-organization-having-the-impact-you-want https://www.amazon.com/Finally-Outcome-Measurement-Strategies-Understand/dp/0578024659 https://www.amazon.com/Great-Nonprofit-Evaluation-Reboot-Understand/dp/193807792X    Connect with Wendy Wolff https://www.linkedin.com/in/wolffwendy/

https://westminster-institute.org/events/challenges-facing-christian-communities-in-turkey-today/ Dr. Hratch Tchilingirian is a sociologist (with a particular reference to sociology of religion) and Associate Faculty Member of Oriental Studies, University of Oxford. He has published extensively and lectures on minorities in contemporary Middle East; inter-ethnic conflicts in the Caucasus, the Armenian Church, Diaspora, and Turkish-Armenian relations. From 2002 to 2012 he taught and held various positions at University of Cambridge, and was co-founder of the Eurasia Research Centre at Judge Business School. Dr. Tchilingirian is the author of numerous studies, articles and publications and has lectured internationally in leading universities, academic institutions and international NGOs (see www.hratch.info). His television, radio and newspaper interviews have appeared in international media outlets, including the New York Times, Financial Times, BBC News, Al-Jazeera and Radio Vaticana. A transcript is unavailable for this talk. Dr. Tchilingirian’s remarks will be a chapter of Handbook of Christianity in the Middle East (eds. Mitri Raheb and Mark A. Lamport). Rowman & Littlefield Publishers, 2021.

Casey Jo Humbyrd, MD, is an Associate Professor of Orthopaedic Surgery in the School of Medicine at Johns Hopkins University. She is an Associate Faculty Member of the Berman Institute of Bioethics, and she completed a Masters of Bioethics at the Berman Institute. Dr. Humbyrd received her B.A. from the University of Pennsylvania and her M.D. from the Mount Sinai School of Medicine. During medical school, she participated in a month-long ethics fellowship at the University of Oxford.  After medical school, Dr. Humbyrd completed her residency in Orthopaedic Surgery at Johns Hopkins School of Medicine followed by a foot and ankle fellowship at Mercy Medical Center. Dr. Humbyrd’s research interest focus on ethical concerns related to surgery in general and orthopedic surgery in particular. Her current primary research interest revolves around the ethics of bundled payment programs for total joint replacement, ethical use of opioids in orthopedic surgery, and disparities in access to orthopedic care. She is a quarterly columnist on orthopedic ethical issues for the journal of Clinical Orthopaedics and Related Research. Nationally, she is involved in advocacy work as a delegate to the American Medical Association and Chair of the health policy committee of the American Orthopaedic Foot and Ankle Society. Dr. Humbyrd is also the faculty advisor for the Johns Hopkins medical student section of MedChi and the AMA.

Ifeoma Ajunwa, professor at the Industrial and Labor Relations School at Cornell, discusses the interplay of law and technology in the multiple stages of an employee’s journey, from algorithms that hire the “ideal” worker to mobile apps that monitor workers’ performance. She points out that many of the legal frameworks used today do not contemplate and do not address the issues that arise from the use of the workplace technologies we have now. Professor Ajunwa offers examples of how hiring algorithms can inherit existing human biases, when left unchecked. And she cautions listeners to read the fine print when signing up for employee wellness programs, as many have been found to sell collected data to third parties.  Professor Ajunwa is an Assistant Professor at the Industrial and Labor Relations School at Cornell University, an Associate Faculty Member at Cornell Law School, and a Faculty Associate at the Berkman Klein Center at Harvard Law School. She holds a PhD in sociology from Columbia University and a law degree from the University of San Francisco School of Law. Links from the Episode at presentvaluepodcast.com Episode Article: Johnson Business Feed Faculty Page: Ifeoma Ajunwa - Industrial and Labor Relations School, Cornell Personal Website: ifeomaajunwa.com Twitter: @iajunwa Research: SSRN Page  

Dr. Sprague is a clinical researcher with expertise in the design and conduct of large randomized controlled trials, observational studies, systematic reviews, and scoping reviews. She obtained a Doctorate Degree in Medical Science from the University of Amsterdam and a Master of Science Degree in Health Research Methodology from McMaster University. She became a Faculty Member with the Department of Surgery in 2014 and serves as an Associate Faculty Member in the Department of Health Research Methods, Evidence, and Impact in 2017. In addition to her faculty appointments, Dr. Sprague serves as the Associate Director at the Centre for Evidence-Based Orthopaedics at McMaster University.

ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. The ASCO Annual Meeting brings together physicians, researchers, patient advocates, and other health care professionals to discuss the latest in cancer care. The research presented at this meeting frequently leads to treatment advances and new ways to improve the quality of life for people with cancer. In today’s podcast, Cancer.Net Associate Editors share their thoughts on the most exciting and practice-changing news to come out of the 2018 ASCO Annual Meeting. First, Dr. Daniel Mulrooney will discuss a large international study on maintenance chemotherapy for rhabdomyosarcoma, and several studies on the benefits of physical activity for survivors of childhood cancer. Dr. Mulrooney is an Associate Faculty Member in the Division of Cancer Survivorship at St. Jude Children’s Research Hospital. He is also the Cancer.Net Associate Editor for Childhood Cancers. Dr. Mulrooney: This is Dr. Dan Mulrooney from St. Jude Children's Research Hospital. I'm the Deputy Director of the After Completion of Therapy Clinic at St. Jude and primarily care for survivors of pediatric solid tumors. During this year's Annual Meeting of the American Society of Clinical Oncology, a very interesting, large, international study investigating maintenance treatment for rhabdomyosarcoma was highlighted during the plenary session. Maintenance chemotherapy, or prolonged low-dose chemotherapy, is used most frequently in the treatment of acute lymphoblastic leukemia, or ALL, but less so for pediatric solid tumors. In a study conducted by the European Paediatric Soft Tissue Sarcoma Study Group that included patients from 14 different countries, investigators studied adding maintenance chemotherapy to the treatment of high-risk rhabdomyosarcoma. Rhabdomyosarcoma is a rare tumor, which mostly occurs in children but can also present in adults. Fortunately, treatment is often successful. But up to 20 to 30 percent of patients may still relapse after treatment meaning additional treatment is needed and making long-term cure more difficult. Standard treatment involves 6 to 8 months of intensive chemotherapy, radiation, and surgery. These investigators wanted to know if adding additional low-dose chemotherapy for six months after standard treatment might improve survival. They studied patients greater than 6 months to less than 21 years of age with high-risk disease based on the histology and location of their tumors. 186 patients were randomized to standard therapy. And 185 were randomized to receive the additional 6 months of maintenance chemotherapy, which included vinorelbine given IV, weekly, for 3 weeks every month, and cyclophosphamide taken orally everyday. And at 5 years, the overall survival was statistically better in the maintenance chemotherapy group, 87% versus 74% in the standard therapy group. Fortunately, toxicity from the additional chemotherapy was minimal and mostly included low blood counts, although approximately 30% of patients also had an infectious complication. These investigators concluded that this additional maintenance therapy is an effective and well-tolerated strategy for patients with high-risk rhabdomyosarcoma and proposed to investigate this method in other solid tumor types. Now additionally, a number of studies presented at the meeting highlighted the importance of physical fitness among childhood cancer survivors. A study from the University of New South Wales in Sydney, Australia collected physical activity data from the parents of childhood cancer survivors and a control population. Fortunately, the parents of survivors reported more physical activity in their children than the control parents with 31% of survivors meeting the recommendations of the American Cancer Society for moderate to vigorous physical activity, which is greater than or equal to 300 minutes of activity per week. However, nearly two-thirds of survivors did not meet the recommended activity level. Subsequently, a large study from the St. Jude Lifetime Cohort assessed 577 childhood cancer survivors, and 286 healthy community controls. In this study, individuals underwent a series of tests including an echocardiogram and cardiopulmonary exercise testing on a treadmill. Measures of relative peak oxygen uptake or “VO2 max” were obtained to assess exercise capacity. Survivors had a lower VO2 max compared to controls, and this worsened with increasing intensity of previous exposure to cardiotoxic therapies such as anthracyclines and chest radiation. This was also associated with a relatively new measure on echocardiography called global longitudinal strain. In fact, global longitudinal strain, and not the more common measure of ejection fraction, was associated with impaired VO2 max among cancer survivors. Global longitudinal strain may become an important new screening marker for cancer survivors. And finally, 2 studies from the Childhood Cancer Survivor Study, or CCSS, highlighted the importance of exercise for childhood cancer survivors. The CCSS is a multi-institutional study that uses questionnaires to assess outcomes among a large population of cancer survivors from across North America. Investigators collected data on physical activity, classified as metabolic equivalent tasks, or METs, and expressed as MET-hours per week. Exercise levels were categorized into groups ranging from none or 0 MET-hours per week and increasing incrementally to 3 to 6, 9 to 12, and 15 to 21 MET-hours per week. 3 to 6 MET-hours per week is equivalent to approximately 20 minutes of brisk walking per week, and 15 to 21 MET-hours per week is equivalent to approximately 60 minutes of brisk walking every day for 5 days per week. And in the first study, investigators showed a decrease in psychological burden among cancer survivors, decreased depression and somatization, and improvements in quality of life and cognitive function among those with increased levels of physical activity. As little as 20 minutes of brisk walking per week was associated with this lower psychological burden. Importantly, in a longitudinal analysis, CCSS investigators showed a decrease in mortality with increasing intensity of physical activity. And looking over eight years, survivors who increased their level of exercise had a 40% reduction in the rate of death compared to those who maintained a low level of exercise. Taken together, these studies presented at the 2018 ASCO Annual Meeting highlight the safety and significant health and psychological benefits of exercise for survivors of childhood cancer. ASCO: Thank you Dr. Mulrooney. Next, Dr. Hyman Muss will discuss a study on a tool that can be used to improve communication between older adults with cancer and their doctors. Dr. Muss is a Professor of Medicine at the University Of North Carolina School Of Medicine, and the Director of the Geriatric Oncology Program at the University of North Carolina Lineberger Comprehensive Cancer Center Program. He is also the Cancer.Net Associate Editor for Geriatric Oncology. Dr. Muss: My name is Hy Muss, and I'm a medical oncologist with a major interest in geriatric oncology. And today I'm going to talk about what I think is 1 of the most exciting studies I've seen in years pertaining to cancer care in older patients, an ASCO presentation by Dr. Supriya Mohile and our colleagues on a large, randomized trial they did, focused on improving communication of older patients with their physician. So this was a very large PCORI-funded trial in the United States, a federally funded study for patients 70 and older with a whole variety of different cancers. And in this study, what happened were older patients were either randomized to an intervention, which included giving a questionnaire, a geriatric assessment, that asked about function and all types of other issues related to older people, social support etc. And together with that information, there were recommendations for the doctor to talk with the patient about, such as if they had poor social support, maybe get them to a senior facility. Or if they had problems getting meals, set up meals on wheels. Or if they had a physical handicap, get them to physical therapy to try to overcome it. So that was all provided to the doctor. And the second group of patients just got kind of very little information sent to the doctor. And so what happened in this trial, which was extremely exciting, was that they had 500 patients accrued to this, so this is a huge number of patients. And about half were given the intervention arm and half were just routine care. And it showed that the patients who went through the intervention, and that information was provided to the doctor, had much better communications with the doctor about their illnesses, about their cancer care. And more importantly, it led to interventions that were very helpful and that probably improved their quality of life and physical well-being, although, these data were not reported in the presentation. And this is really special, because the standard care arm, a lot of things were not discussed, and a lot of things that older patients had may not be related to their cancer but are extremely important for the oncologist to know. And these are things like, "How are you doing at home? Are you able to care for yourself? Do you pay your bills? Do you have good social support? Can you go to the grocery store, etc.? Also, what are your friends like? What are your family like? Do you have people interested in you that take you out, do things?" And frequently, those issues aren't discussed, and they're integral to the care of older people. So they showed the value of a geriatric assessment, which discovers many more things than the usual questions doctors ask you in 1 or 2 sentences about your function. And more importantly, they improved care, they improved communication, and they led to interventions that make people's lives better, and perhaps, someday a lot longer. So I thought this was a terrific study. Dr. Mohile and her colleagues broke the glass on showing how important geriatric assessment—where we ask questions about your function, about your health and other things, that are generally not part of a routine history and physical—how important this is to improving care. So I hope you take a look at this at the ASCO site. It's a wonderful trial, and I think it's the beginning of many more similar trials to come. Thank you. ASCO: Thank you Dr. Muss. Next, Dr. Michael Thompson will discuss several topics in multiple myeloma that were explored at the 2018 ASCO Annual Meeting, including a discussion on the cost and value of myeloma drugs, a study that compared different doses of a treatment for relapsed refractory multiple myeloma, and several studies that explored ways to personalize myeloma treatment, also known as precision medicine. Dr. Thompson is a hematologist/oncologist, and the Medical Director for the Early-Phase Cancer Research Program and the Oncology Precision Medicine Program at Aurora Health Care in Wisconsin. He is also the Cancer.Net Associate Editor for Multiple Myeloma. Dr. Thompson: Hello. I'm Mike Thompson, a hematologist/oncologist at Aurora Health Care of Wisconsin. I'm also the Associate Editor for Cancer.Net on myeloma. Today, I'm going to discuss a few myeloma-related areas reported at the ASCO 2018 Annual Meeting. The first is a value debate, which was on Sunday, between Mayo colleagues and friends, Dr. Fonseca and Dr. Rajkumar, who had discussed the question of costs and value in multiple myeloma in this session, Global Myeloma, Health Disparities, and the Cost of Drugs. They disagreed on some issues. But my take-home from their debate was that both the absolute costs of care as well as value, which was utility divided by cost, are important to our entire healthcare system as well as to patients and their families. There was no immediate changes to costs of care after that debate, but I think it's something important that we will all be watching as new drugs are developed in the future. Another important study was the A.R.R.O.W. study, which was reported on by Dr. Mateos, and was later published with the first author, Dr. Moreau. This was a phase III study of 2 different doses of carfilzomib with dexamethasone in relapsed and refractory myeloma patients. So there was the traditional twice-weekly dose, and there was the once-weekly dose. And the conclusions were that the once-weekly dose with a dose up to 70 milligrams per meter squared improved progression-free survival and overall response rate. And later in the publication, it showed that it improved survival versus the twice-weekly dose at 27 milligrams per meter squared, with a similar side effect profile. So that is very good news for patients that might get that doublet therapy and have to come into the office less frequently. The caveats with that study are that this dosing was not compared to an intermediate dose of 56 milligrams per meter squared, which has been widely used after that study was published a few years ago. So it's looking at the lowest dose versus the highest dose. And it's also for patients with a performance status of 0 to 1, which means they're doing well. And for many of those patients, we wouldn't use a doublet therapy; we'd use a triplet therapy. So that may limit the applicability in practice, at least, in the United States. And we also don't know that combining this Kd regimen with another myeloma drug is safe or effective, so those studies are ongoing. And the third topic that was of interest at ASCO 2018 was precision medicine in multiple myeloma. So there were at least 3 parts to this. One is risk stratification. And this has been going on for a while, looking at the cytogenetics and FISH. And the NCCN and Mayo mSMART guidelines give some guidance on how to treat based on risk. Also there was talk about the CAR-T therapies, which may be the most specific or precision type of medicine you can get. And those studies are ongoing but not yet widely available for myeloma, but everyone is very interested in those data. Other therapies were targeted therapies, and there are not as many examples in multiple myeloma as there are in some diseases like lung cancer. But there are some alterations such as BRAF, where BRAF inhibitors are used or can be used in a few patients, in myeloma that have that. And there's great excitement about the BCL-2 inhibitor or venetoclax for t(11;14), which is the most common translocation found in multiple myeloma. So those are some of the main things I took away from this ASCO meeting. We really need to think about costs and value and the impact it has on our patients. We need to think about trying to dose drugs in ways that are more convenient to patients, and in this case, seemed to be more beneficial. And we have to keep looking ahead to do more things with targeted therapies to see if we can get away from some of the toxicities of some of our chemotherapy agents. Coming up will be more studies over the next year for ASCO 2019, and I look forward to seeing what changes between now and then. ASCO: Thank you Dr. Thompson. Finally, Dr. Jyoti Patel will discuss the ongoing research in targeted therapy and precision medicine for lung cancer. Dr. Patel is Professor of Medicine and Director of Thoracic Oncology at the University of Chicago and is the Cancer.Net Associate Editor for lung cancer. Dr. Patel: Hello. I'm Jyoti Patel. I'm the Director of Thoracic Oncology at the University of Chicago and a long-time ASCO member, and I would like to talk to you today about some of the most important research takeaways from our recent ASCO Annual Meeting. So remember, this is a meeting where about 40,000 cancer care providers come together to discuss and to present the most groundbreaking research and its impact for patients. So this is certainly a meeting that is exciting for all of us and really represents, I think, the best of what's happening in the field. I think when we look at what's happening with lung cancer—because there's so many people affected with lung cancer in the United States where nearly 200,000 people every year are diagnosed with lung cancer—we can say that we've made significant leaps forward in the past decade, and it's really changed the paradigm in how we treat patients with advanced disease. So it's a disease in which systemic therapy is really the mainstay of therapy because it's not confined to the lung where we may do surgery or radiation, this is really a disease that has spread and is treated as a more chronic condition. Our efforts at understanding the biology of cancer have really now come back to the bedside, and many of the groundbreaking research trials that were presented really revolved around this idea of personalization of therapy based on biomarkers. Understanding the cancer genome now has a direct impact for our patients. When patients are diagnosed with advanced disease, I think all of these studies point to the fact that we need to have adequate characterization of the tumor. So it's no longer okay to say my patient has non-small cell lung cancer, which is the most common kind of lung cancer, it's really incumbent upon the oncologist, and pathologist, and pulmonologist, and surgeon to come together and further define whether or not there are particular mutations that would serve as good targets for drugs, or whether this is an inflamed tumor and may be best treated with immunotherapy. When someone's diagnosed with lung cancer, I know it's often difficult for a patient, or family member, to first meet the oncologist and say yes, we have this diagnosis, but I'm waiting for additional tests. But that time that it takes to do this testing—and it's very complex, we look at anywhere from 3, at the very minimum, to almost 1,000 genes at my institution's program—in which we try to match particular drugs with therapies. And the reason we do this is because in about 30 or 40 percent of patients with non-small cell lung cancer that's non-squamous, the most common kind, we're able to find an easily druggable target. So we find EGFR and ALK and ROS1, and so we've got updates on all of those targets at ASCO. But this year there was really a lot of excitement about a new target called the RET fusion protein and when 2 chromosomes sort of flip-flop and form a protein that causes this cancer to grow. Now this is uncommon, and medically it affects about 1 to 2 percent of patients with lung cancer, but when you look at the enormous burden of lung cancer, that's thousands of patients a year. What we found was that there's a really selective drug that targets this protein and can shut down the cancer cells and cause deep responses, so almost 80 percent of patients with significant reduction in their tumor and lung responses with an oral tablet that's very well-tolerated. The idea is that we need to absolutely try to do a biopsy, understand if there are multiple markers, and that list continues to grow for which there are druggable targets. And there was a lot of excitement about drugs that target genes such as the MET exon 14 oncogene, or something that's been very elusive for some time, the EGFR exon 20 mutations. These are single sort of base misreads in our DNA that causes cancer to grow, but if 1 patient has this target, and we're able to deliver a drug that causes patients to have nice responses and a return to wellness, I think that's great for all of us. Often getting the right tissue is tough because sometimes we just don't have enough tissue. And, certainly, we've seen considerable progress with liquid biopsies in recent years, and there's been good concordance between blood-based biopsies as well as tissue, and so our field is rapidly evolving in ways that we can bring the best drugs to the best patients. We're starting to do this with immunotherapy. There's a protein called PD-L1 which helps us assign appropriate therapy for patients. And so if someone has a high PD-L marker on their tumor, those patients may get immunotherapy alone with an expectation that they would have a nice response and durable disease control with good quality-of-life. So with effort to really characterize tumors, although it can be difficult when someone's first diagnosed to wait to get all these markers right, which is on the order of about 2 to 3 weeks, the downstream effects of characterizing the tissue and getting the right drugs to the right patients are really enormous because we are able to see patients that return to wellness. Certainly this was an exciting meeting. And I think more and more we're seeing not only medical oncologists, but patients and patient advocates, understanding the importance of biopsies, and an incredible effort by industry, as well, to really make these assays and these tests more accessible to patients, and to make the turnaround times even faster, and to use less tissue to get the right answers. I'm optimistic that we'll continue to see this trend, and there will be more and more drugs that will be optimized for particular patients. ASCO: Thank you Dr. Patel. If this podcast was useful, please take a minute to subscribe, rate, and review the show on Apple Podcasts or Google Play. To learn more about all of the science presented at the 2018 ASCO Annual Meeting, visit www.cancer.net/ascoannualmeeting. If you have questions about whether new research may affect your care, be sure to talk with your doctor. Cancer.Net is supported by ASCO’s Conquer Cancer Foundation, which funds breakthrough research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at conquer.org/support.

On this episode of Talking Late Night, Max talks with Matt Elwell, Executive Director of CSz Worldwide and an improv teacher and performer. Matt got involved with comedy (after years of performing theatre) when he watched his first improv show in Chicago. Since then, Matt has been a performer with multiple improv theatres and shows including ComedySportz, Second City, iO, and Dave & Co. In addition to performing, Matt has taught at Dave & Co., ComedySportz Chicago, and was also an Associate Faculty Member of the Second City Training Center in Chicago. Today, Matt is the Executive Director of CSz Worldwide (the company that operates ComedySportz Shows) and is also a corporate speaker and trainer who, using improv, has worked with many companies all over the United States. To learn more about CSz and ComedySportz you can check them out on their website! To learn more about Matt, you can find him on LinkedIn.  Thank you for tuning in! Be sure to like and share our Facebook page here, and also rate and leave us a review on iTunes!